plixorafenib   Click here for help

GtoPdb Ligand ID: 9131

Synonyms: PLX 8394 | PLX-8394 | PLX8394
Compound class: Synthetic organic
Comment: PLX8394 is an investigational orally available, next-generation small molecule RAF inhibitor [2]. It has potential antineoplastic activity. Structurally, PLX8394 is similar to the first-generation BRAF inhibitor vemurafenib. PLX8394 inhibits wild-type and mutated forms of BRAF. PLX8394 and compounds like it have been termed 'paradox breakers' as they are designed to inhibit mutant BRAF kinase activity without activating the MAPK pathway in cells bearing upstream activation, as many of the original BRAF inhibitors are prone to do. PLX8394 is one of the compounds claimed in patent WO2014194127 [1]. This chemical structure is identical to that of the INN plixorafenib.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 129.32
Molecular weight 542.13
XLogP 3.5
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES FC1CCN(C1)S(=O)(=O)Nc1ccc(c(c1F)C(=O)c1c[nH]c2c1cc(cn2)c1cnc(nc1)C1CC1)F
Isomeric SMILES F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(c(c1F)C(=O)c1c[nH]c2c1cc(cn2)c1cnc(nc1)C1CC1)F
InChI InChI=1S/C25H21F3N6O3S/c26-16-5-6-34(12-16)38(36,37)33-20-4-3-19(27)21(22(20)28)23(35)18-11-32-25-17(18)7-14(8-31-25)15-9-29-24(30-10-15)13-1-2-13/h3-4,7-11,13,16,33H,1-2,5-6,12H2,(H,31,32)/t16-/m1/s1
No information available.
Summary of Clinical Use Click here for help
PLX8394 is being evaluated in a Phase 1/2 clinical trial (NCT02428712) in patients with advanced, unresectable solid tumors.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02428712 A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors Phase 1/Phase 2 Interventional Plexxikon